PMID: 19939228Nov 27, 2009Paper

MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings

Current Alzheimer Research
Marco PaganiFlavio Nobili

Abstract

Patients with Mild Cognitive Impairment (MCI) not converted to dementia at one to three years follow-up represent a heterogeneous group across studies, by including 'late converters' but also patients without any neurodegenerative disease. We tested the hypothesis that the combination of memory and brain metabolic assessment could identify subgroups of memory decliners (MCI/Decl) and non-decliners (MCI/noDecl) before a long follow-up time is available. From twenty-nine patients with amnestic MCI (aMCI) at baseline, three groups were identified at follow-up: 10 patients who converted to AD (MCI/AD); 10 patients either showing episodic memory worsening or reaching the floor effect on memory and declining in other key tests (MCI/Decl) and 9 patients showing no memory worsening or even improvement (MCI/noDecl). They were compared with a group of fourteen elderly controls (CTR) by means of basal FDG-PET voxel-based analysis (SPM2). Two hypometabolic clusters were found in MCI/AD versus CTR, including the bilateral posterior cingulate cortex, the left parietal precuneus and the left fusiform gyrus. MCI/AD showed also a large hypometabolic region, mainly including the left medium and superior temporal gyri and inferior parietal lobule...Continue Reading

Citations

Jun 29, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Giovanni Lucignani, Flavio Nobili
Nov 18, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Angelina CistaroMarco Pagani
May 30, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Javier ArbizuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 19, 2013·PloS One·Marco AlessandriniOrazio Schillaci
Sep 17, 2013·PloS One·Angela Rizk-JacksonMichael Weiner
Jan 22, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Angelina CistaroAdriano Chiò
Nov 23, 2010·NeuroImage·Penny D RihaF Gonzalez-Lima
Jun 13, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Silvia MorbelliUNKNOWN European Association of Nuclear Medicine
May 28, 2016·Journal of Alzheimer's Disease : JAD·Bernard HanseeuwAdrian Ivanoiu
Jul 17, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bernard J HanseeuwKeith A Johnson
May 18, 2016·PloS One·Xueqi ChenUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Apr 5, 2018·Alzheimer's Research & Therapy·Matteo BaucknehtSilvia Morbelli
Jan 30, 2015·The Cochrane Database of Systematic Reviews·Nadja SmailagicChristos Sachpekidis
Aug 9, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Silvia MorbelliFlavio Nobili
Apr 29, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Javier ArbizuUNKNOWN EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Jul 1, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Marco PaganiFabrizio De Carli
Mar 11, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Marco PaganiFlavio Nobili

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.